DONGIOVANNI, PAOLA
DONGIOVANNI, PAOLA
DIPARTIMENTO DI MEDICINA INTERNA (attivo dal 01/01/1998 al 27/04/2012)
Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19]
2024 F. Salomone, R. Pipitone, M. Longo, F. Malvestiti, A. Amorini, A. Distefano, E. Casirati, E. Ciociola, N. Iraci, L. Leggio, R. Zito, N. Vicario, C. Saoca, V. Männistö, J. Pihlajamäki, S. Qadri, H. Yki-Järvinen, S. Romeo, G. Pennisi, D. Cabibi, G. Lazzarino, A. Fracanzani, P. Dongiovanni, L. Valenti, S. Petta, G. Volti, S. Grimaudo
The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
2023 E. Paolini, M. Longo, M. Meroni, G. Tria, A. Cespiati, R. Lombardi, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
Recent advances of drugs monitoring in oral fluid and comparison with blood
2023 S. Casati, M. Binda, P. Dongiovanni, M. Meroni, A. D'Amato, G. Roda, M. Orioli, M. DEL FABBRO, G.M. Tartaglia
Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH
2023 M.P. Moore, X. Wang, H. Shi, M. Meroni, A. Cherubini, L. Ronzoni, E.J. Parks, J.A. Ibdah, R.S. Rector, L. Valenti, P. Dongiovanni, I. Tabas
Quality-by-Design R&D of a Novel Nanozyme-Based Sensor for Saliva Antioxidant Capacity Evaluation
2023 R. Goldoni, D.V. Thomaz, L. Strambini, M. Tumedei, P. Dongiovanni, G. Isola, G. Tartaglia
An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
2023 A. Cespiati, F. Cinque, M. Meroni, R. Lombardi, P. Dongiovanni, A.L. Fracanzani
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
2023 A. Cherubini, M. Ostadreza, O. Jamialahmadi, S. Pelusi, E. Rrapaj, E. Casirati, G. Passignani, M. Norouziesfahani, E. Sinopoli, G. Baselli, C. Meda, P. Dongiovanni, D. Dondossola, N. Youngson, A. Tourna, S. Chokshi, E. Bugianesi, E. Study Investigators, S. DELLA TORRE, D. Prati, S. Romeo, L. Valenti
Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation
2023 P. Dongiovanni, M. Meroni, S. Casati, R. Goldoni, D.V. Thomaz, N.S. Kehr, D. Galimberti, M. Del Fabbro, G.M. Tartaglia
Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis
2023 J. Kang, J. Postigo-Fernandez, K. Kim, C. Zhu, J. Yu, M. Meroni, B. Mayfield, A. Bartolomé, D.H. Dapito, A.W. Ferrante, P. Dongiovanni, L. Valenti, R.J. Creusot, U.B. Pajvani
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease
2023 R.M. Pipitone, F. Malvestiti, G. Pennisi, O. Jamialahmadi, P. Dongiovanni, G. Bertolazzi, J. Pihlajamäki, H. Yki-Järvinen, U. Vespasiani-Gentilucci, F. Tavaglione, S. Maurotti, C. Bianco, G. Di Maria, M. Enea, A.L. Fracanzani, V. Kärjä, G. Lupo, V. Männistö, M. Meroni, R. Piciotti, S. Qadri, R. Zito, A. Craxì, V. Di Marco, C. Cammà, C. Tripodo, L. Valenti, S. Romeo, S. Petta, S. Grimaudo
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
2022 M. Longo, M. Meroni, E. Paolini, V. Erconi, F. Carli, F.R. Fortunato, D. Ronchi, R. Piciotti, S. Sabatini, C. Macchi, A. Alisi, L. Miele, G. Soardo, G.P. Comi, L.V.C. Valenti, M. Ruscica, A.L. Fracanzani, A. Gastaldelli, P. Dongiovanni
{PD}-1/{PD}-L1 Immuno-Mediated Therapy in {NAFLD}: Advantages and Obstacles in the Treatment of Advanced Disease
2022 R. Lombardi, R. Piciotti, P. Dongiovanni, M. Meroni, S.R. Fargion, A.L. Fracanzani
Rare ATG7 genetic variants predispose patients to severe fatty liver disease
2022 G.A. Baselli, O. Jamialahmadi, S. Pelusi, E. Ciociola, F. Malvestiti, M. Saracino, L. Santoro, A. Cherubini, P. Dongiovanni, M. Maggioni, C. Bianco, F. Tavaglione, A. Cespiati, R.M. Mancina, R. D'Ambrosio, V. Vaira, S. Petta, L. Miele, U. Vespasiani-Gentilucci, A. Federico, J. Pihlajamaki, E. Bugianesi, A.L. Fracanzani, H.L. Reeves, G. Soardo, D. Prati, S. Romeo, L.V. Valenti
Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown
2022 F. Cinque, A. Cespiati, R. Lombardi, A. Costantino, G. Maffi, F. Alletto, L. Colavolpe, P. Francione, G. Oberti, E. Fatta, C. Bertelli, G. Sigon, P. Dongiovanni, M. Vecchi, S. Fargion, A.L. Fracanzani
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system
2022 M. Meroni, E. Paolini, M. Longo, R. Piciotti, G. Tria, S. Fargion, A. Ludovica Fracanzani, P. Dongiovanni
Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
2022 M. Meroni, M. Longo, E. Paolini, G. Tria, M. Ripolone, L. Napoli, M. Moggio, A.L. Fracanzani, P. Dongiovanni
Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
2022 A. Cespiati, M. Meroni, R. Lombardi, G. Oberti, P. Dongiovanni, A.L. Fracanzani
MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients
2022 M. Meroni, M. Longo, E. Paolini, R. Lombardi, R. Piciotti, P. Francione, S. Badiali, M. Maggioni, A.L. Fracanzani, P. Dongiovanni
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease
2021 S. Grimaudo, P. Dongiovanni, J. Pihlajamaki, M. Eslam, H. Yki-Jarvinen, R.M. Pipitone, G. Baselli, C. Camma, V. Di Marco, M. Enea, M. Longo, G. Pennisi, D. Prati, R. Zito, A.L. Fracanzani, A. Craxi, J. George, S. Romeo, L. Valenti, S. Petta
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
2021 N. Panera, M. Meroni, M. Longo, A. Crudele, L. Valenti, E. Bellacchio, L. Miele, V. D'Oria, E. Paolini, M. Maggioni, A.L. Fracanzani, A. Alisi, P. Dongiovanni